WeTrials
Completed

A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes

What is this study?

This study tests a new weekly insulin medication called insulin efsitora alfa to see how well it works compared to a standard daily insulin called insulin glargine. It aims to help adults with Type 2 diabetes who are starting insulin for the first time better manage their blood sugar levels.

Who can participate?

You might be able to join if you are an adult with Type 2 diabetes who has never used insulin before, but needs to start because your blood sugar is not controlled by pills alone. You must also meet specific health guidelines and have stable blood sugar levels during screening.

What will happen?

Participants will be randomly assigned to receive either the new weekly insulin injection or the standard daily insulin injection. You will be closely monitored by the study team to track your blood sugar levels, overall health, and safety throughout the process.

Where and when?

This study has been completed and took place at multiple locations, including research centers in Alabama and California within the United States.

Key Points
  • 1Testing a new weekly insulin compared to a standard daily insulin
  • 2Designed for adults with Type 2 diabetes starting insulin for the first time
  • 3The study has successfully finished its trial run

Related video

Type 2 Diabetes: Could Insulin Be Once a Week Instead of Daily?

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Type 2 DiabetesT2D

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.